drugs for teh management of ptsd
Reading File
Finding Sources
Searching PubMed
"post-traumatic stress disorder"[MeSH Terms] AND "drug therapy"[MeSH Terms]
Finding Sources
Searching PubMed
"PTSD" AND "pharmacotherapy"
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
I now have comprehensive data from multiple authoritative sources. Here is the full answer:
Pharmacological Management of PTSD
Psychotherapy (trauma-focused CBT, EMDR, prolonged exposure) is the cornerstone of PTSD treatment. Drugs are adjuncts - used when psychotherapy is unavailable, refused, or insufficient, and to target specific symptom clusters and comorbidities.
First-Line Drugs
| Drug | Key Points |
|---|---|
| Sertraline (SSRI) | FDA-approved for PTSD; preferred SSRI |
| Paroxetine (SSRI) | FDA-approved for PTSD; preferred SSRI |
| Fluoxetine (SSRI) | Preferred SSRI; well-supported evidence |
| Venlafaxine MR (SNRI) | Recommended by NICE; 35-300 mg/day; supported by multiple meta-analyses |
All SSRIs/SNRIs should be started at low doses (they can initially exacerbate anxiety) and titrated up to maximum licensed doses before declaring failure.
Second-Line Drugs
Antidepressants
- Mirtazapine 15-45 mg/day - NICE recommended; second most effective drug in a network meta-analysis; particularly useful for sleep/nightmares
- Tricyclics (TCAs) - supported by systematic review and meta-analysis:
- Amitriptyline 50-300 mg/day (NICE recommended)
- Imipramine 50-300 mg/day
- Note: best TCA evidence is for desipramine, but it is not widely available
- Phenelzine (MAOI) 15-75 mg/day - ranked the most effective drug in one network meta-analysis; reserved for refractory cases due to dietary restrictions and drug interactions
Antipsychotics (target intrusion symptoms - flashbacks and nightmares - but generally NOT avoidance or hyperarousal):
- Olanzapine 5-20 mg - may be most effective among antipsychotics
- Quetiapine 50-800 mg - more robust evidence than risperidone; NICE-mentioned
- Risperidone 0.5-6 mg - specifically mentioned by NICE
Alpha-1 blocker
- Prazosin 2-15 mg at night - specifically targets PTSD-related nightmares and sleep disturbance; start at 1 mg at night and titrate slowly to minimize orthostatic hypotension
Emerging / Investigational
| Drug | Status |
|---|---|
| Ketamine IV | Rapid reduction in symptom severity; growing acute and chronic efficacy data |
| MDMA-assisted psychotherapy | Phase III trials completed for severe/refractory PTSD; acts as adjunct to intensive psychotherapy (not standalone) |
| Duloxetine | Two small open studies show efficacy |
| Topiramate | Reduces intrusion and avoidance; evidence from Harrison's |
| Stellate ganglion block | Procedural intervention showing emerging efficacy |
What to Avoid / Use with Caution
- Benzodiazepines - useful only for short-term crisis management; should not be given in the immediate aftermath of trauma (may worsen PTSD outcomes)
- Escitalopram, hydrocortisone, intranasal oxytocin given acutely post-trauma to prevent PTSD have shown equivocal results
Symptom-Targeted Summary
| Symptom cluster | Preferred drug(s) |
|---|---|
| Overall PTSD (all clusters) | SSRIs, venlafaxine |
| Nightmares / sleep disturbance | Prazosin, mirtazapine, trazodone (low dose) |
| Intrusion / flashbacks | Antipsychotics (adjunct) |
| Refractory / severe | Phenelzine, MAOI, ketamine |
| Comorbid depression | SSRIs, mirtazapine, TCAs |
Notable 2025 Trial (PubMed)
A Phase III RCT published in JAMA Psychiatry (2025) evaluated brexpiprazole + sertraline as a combination in PTSD [PMID: 39693081], suggesting adjunctive atypical antipsychotics continue to be explored as augmentation strategies.
Sources:
- The Maudsley Prescribing Guidelines in Psychiatry, 15th ed., Box 3.8 (PTSD)
- Harrison's Principles of Internal Medicine, 22nd ed., Chapter on Stress Disorders
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry (anxiety/PTSD pharmacology)
- Stahl's Essential Psychopharmacology, PTSD chapter
Create a quick reference comparing first-line PTSD drugs
Asking for Preferences
Here is the quick reference:
First-Line PTSD Drugs - Quick Reference
| Drug | Class | FDA Approved for PTSD | Usual Dose | Key Advantages | Key Disadvantages | Start Low? |
|---|---|---|---|---|---|---|
| Sertraline | SSRI | Yes | 50-200 mg/day | Best-evidenced; safe in comorbidities; once daily | Sexual dysfunction; initial anxiety worsening; GI upset | Yes - start 25 mg |
| Paroxetine | SSRI | Yes | 20-60 mg/day | FDA-approved; sedating (helps sleep) | Worst discontinuation syndrome of SSRIs; weight gain; anticholinergic effects | Yes - start 10 mg |
| Fluoxetine | SSRI | No (off-label) | 20-60 mg/day | Long half-life - fewer missed-dose effects; no discontinuation syndrome | More activating (can worsen hyperarousal initially); drug interactions (CYP2D6) | Yes - start 10 mg |
| Venlafaxine MR | SNRI | No (off-label) | 75-300 mg/day | NICE-recommended; dual NE+5HT action; useful for comorbid depression/pain | Dose-dependent hypertension; discontinuation syndrome; nausea | Yes - start 37.5 mg |
At a Glance - Symptom Coverage
| Symptom Domain | Sertraline | Paroxetine | Fluoxetine | Venlafaxine MR |
|---|---|---|---|---|
| Re-experiencing / intrusions | + | + | + | + |
| Avoidance | + | + | + | + |
| Hyperarousal | + | + | + | + |
| Sleep / nightmares | Moderate | Moderate (sedating) | Low | Moderate |
| Comorbid depression | + | + | + | ++ |
| Comorbid anxiety | + | + | + | ++ |
Practical Notes
- All four should be trialed for at least 8-12 weeks at adequate dose before switching.
- Start at half the target dose - SSRIs/SNRIs can transiently worsen anxiety in the first 1-2 weeks.
- If nightmares persist on any of these, add prazosin at night (2-15 mg) rather than switching.
- Sertraline is generally the default first choice given its FDA approval, tolerability profile, and the breadth of evidence.
- Venlafaxine MR is the preferred option when there is prominent comorbid depression or a prior SSRI failure.
- Paroxetine's sedating profile can be useful in patients with marked sleep disruption, but its withdrawal syndrome requires slow tapering.
Sources: Maudsley Prescribing Guidelines 15th ed., NICE Guidelines, Harrison's 22nd ed.
This is a shared conversation. Sign in to Orris to start your own chat.